SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies

KIZ OpenIR > 管理、支撑部门 > 实验动物中心

	SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
	Wei, WW; Ma, HY; Yang, D; Sun, B; Tang, J; Zhu, YJ; Chen, XC; Huang, XO; Liu, JZ; Hu, ZF; Liu, T; Zou, LQ; Zhao, XD
	2023
发表期刊	BLOOD ADVANCES
ISSN	2473-9529
卷号	7 期号:13 页码:2941-2951
摘要	CD7 has been found to be a promising chimeric antigen receptor (CAR) T cell target in several clinical trials. However, its expression on normal T cells poses additional challenges in CD7-directed CAR therapy, such as complete fratricide, contamination with malignant cells, and immune suppression due to T-cell aplasia. By taking advantage of evolved affinity between ligand and receptor, we constructed a CD7-directed CAR with the extracellular domain of SECTM1, a natural ligand of CD7, as the recognition domain. SECTM1 CAR T cells killed the majority of T cells with high CD7 expression in vitro. However, SECTM1 CAR T cells with low or negative CD7 expression survived, expanded, and showed strong cytotoxicity to CD7+ malignant cell lines and primary leukemic blasts from patients with T-cell acute lymphoblastic leukemia and acute myelogenous leukemia in vitro. It also exhibited efficacy in inhibiting xenograft tumor growth in vivo. More exploration is needed for clinical efficacy potential to patients with CD7+ malignancies.
收录类别	SCI
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/14396
专题	管理、支撑部门_实验动物中心
推荐引用方式 GB/T 7714	Wei, WW,Ma, HY,Yang, D,et al. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies[J]. BLOOD ADVANCES,2023,7(13):2941-2951.
APA	Wei, WW.,Ma, HY.,Yang, D.,Sun, B.,Tang, J.,...&Zhao, XD.(2023).SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.BLOOD ADVANCES,7(13),2941-2951.
MLA	Wei, WW,et al."SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies".BLOOD ADVANCES 7.13(2023):2941-2951.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2024053135.pdf（1424KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文